Serum levels of <i>hsa‐miR‐16‐5p</i>, <i>hsa‐miR‐29a‐3p</i>, <i>hsa‐miR‐150‐5p</i>, <i>hsa‐miR‐155‐5p</i> and <i>hsa‐miR</i>‐<i>223‐3p</i> and subsequent risk of chronic lymphocytic leukemia in the EPIC study
Delphine Casabonne, Yolanda Benavente, Julia Seifert, Laura Costas, María Armesto, María Arestin, Caroline Besson, Fatemeh Saberi Hosnijeh, Eric J. Duell, Elisabete Weiderpass, Giovanna Masala, Rudolf Kaaks, Federico Canzian, María‐Dolores Chirlaque, Vittorio Perduca, Francesca Romana Mancini, Valeria Pala, Antonia Trichopoulou, Anna Karakatsani, Carlo La Vecchia, María‐José Sánchez, Rosario Tumino, Marc J. Gunter, Pilar Amiano, Salvatore Panico, Carlotta Sacerdote, Julie A. Schmidt, Heiner Boeing, Matthias B. Schulze, Aurelio Barricarte, Elio Riboli, Anja Olsen, Anne Tjønneland, Roel Vermeulen, Alexandra Nieters, Charles H. Lawrie, Sílvia de Sanjosé (2020). Serum levels of <i>hsa‐miR‐16‐5p</i>, <i>hsa‐miR‐29a‐3p</i>, <i>hsa‐miR‐150‐5p</i>, <i>hsa‐miR‐155‐5p</i> and <i>hsa‐miR</i>‐<i>223‐3p</i> and subsequent risk of chronic lymphocytic leukemia in the EPIC study. , 147(5), DOI: https://doi.org/10.1002/ijc.32894.
